La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Shockwave Medical Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Doug Godshall

Amministratore delegato

US$9.5m

Compenso totale

Percentuale dello stipendio del CEO	7.6%
Mandato del CEO	7yrs
Proprietà del CEO	0.3%
Durata media del management	2.3yrs
Durata media del Consiglio di amministrazione	5.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Doug Godshall rispetto agli utili di Shockwave Medical?
Data	Compenso totale	Stipendio	Guadagni aziendali
Mar 31 2024	n/a	n/a	US$163m
Dec 31 2023	US$9m	US$716k	US$147m
Sep 30 2023	n/a	n/a	US$244m
Jun 30 2023	n/a	n/a	US$244m
Mar 31 2023	n/a	n/a	US$241m
Dec 31 2022	US$8m	US$644k	US$216m
Sep 30 2022	n/a	n/a	US$88m
Jun 30 2022	n/a	n/a	US$55m
Mar 31 2022	n/a	n/a	US$29m
Dec 31 2021	US$7m	US$575k	-US$9m
Sep 30 2021	n/a	n/a	-US$38m
Jun 30 2021	n/a	n/a	-US$53m
Mar 31 2021	n/a	n/a	-US$71m
Dec 31 2020	US$5m	US$546k	-US$66m
Sep 30 2020	n/a	n/a	-US$65m
Jun 30 2020	n/a	n/a	-US$65m
Mar 31 2020	n/a	n/a	-US$57m
Dec 31 2019	US$2m	US$477k	-US$51m
Sep 30 2019	n/a	n/a	-US$48m
Jun 30 2019	n/a	n/a	-US$45m
Mar 31 2019	n/a	n/a	-US$44m
Dec 31 2018	US$511k	US$376k	-US$41m

Compensazione vs Mercato: La retribuzione totale di Doug ($USD 9.48M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 5.47M ).

Compensazione vs guadagni: La retribuzione di Doug è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Doug Godshall (58 yo)

7yrs

Mandato

US$9,478,729

Compensazione

Mr. Douglas E. Godshall, also known as Doug, M.B.A., is Director of Saluda Medical, Inc. He serves as Chair of the Board of Galvanize Therapeutics, Inc. since September 2022. He has been the Chief Executiv...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Douglas Godshall	President	7yrs	US$9.48m	0.29% $ 33.7m
Isaac Zacharias	President & Chief Commercial Officer	1.9yrs	US$3.23m	0.15% $ 17.4m
Daniel Hawkins	Founder and Senior Advisor	15.3yrs	Nessun dato	Nessun dato
John Adams	Co-Founder and Technical Advisor	15.3yrs	Nessun dato	Nessun dato
Renee Gaeta	Chief Financial Officer	less than a year	Nessun dato	0.053% $ 6.1m
Luis Morales	Senior Vice President of Global Operations	less than a year	Nessun dato	Nessun dato
Trinh Phung	Chief Accounting Officer	2.3yrs	Nessun dato	0.13% $ 15.5m
Debbie Kaster	Vice President of Investor Relations	less than a year	Nessun dato	Nessun dato
Hajime Tada	General Counsel & Secretary	4.9yrs	Nessun dato	Nessun dato
Robert Fletcher	Senior Vice President of Marketing & Market Access	7.8yrs	Nessun dato	Nessun dato
Dave Cox	Vice President of Sales	less than a year	Nessun dato	Nessun dato
Cathy Harnett	Senior Director of Human Resources	2.3yrs	Nessun dato	Nessun dato

2.3yrs

Durata media

52yo

Età media

Gestione esperta: Il team dirigenziale di 36M è considerato esperto (durata media dell'incarico 2.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Douglas Godshall	President	7yrs	US$9.48m	0.29% $ 33.7m
Antoine Papiernik	Independent Director	10.8yrs	US$277.06k	Nessun dato
Frederic Moll	Independent Director	13yrs	US$273.62k	0.76% $ 88.2m
Charles Larkin	Independent Chairman of the Board	5.3yrs	US$333.62k	0.012% $ 1.4m
Laura Francis	Independent Director	5.3yrs	US$297.37k	0.011% $ 1.2m
Sara Toyloy	Independent Director	3.2yrs	US$278.62k	0.0052% $ 600.0k
Maria Sainz	Independent Director	3.8yrs	US$289.87k	0.0096% $ 1.1m
Kevin Ballinger	Independent Director	less than a year	US$508.05k	Nessun dato
F. Watkins	Independent Director	10.9yrs	US$278.62k	0.010% $ 1.2m

5.3yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 36M sono considerati esperti (durata media dell'incarico 5.3 anni).

Shockwave Medical Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Shockwave Medical, Inc., Annual General Meeting, May 29, 2024

Insufficient new directors

Independent Director recently sold €14m worth of stock

Shockwave Medical, Inc. Appoints Renee Gaeta as Chief Financial Officer, Effective February 5, 2024

Shockwave Medical, Inc. Appoints Nick West as Associate Chief Medical Officer

Recent updates

Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter

Shockwave Medical Files Form 15

Shockwave's Common Stock Ceases Trading on NASDAQ

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers.

Shockwave Medical Withdraws Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$1.48 (vs US$1.07 in 1Q 2023)

Shockwave Medical, Inc., Annual General Meeting, May 29, 2024

Shockwave Medical, Inc. Announces Investigators Presented Six-Month Data from the Full Population of the Reducer-I Study

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Insufficient new directors

Johnson & Johnson Reportedly Considers Deal for Shockwave Medical

Now 21% undervalued

New minor risk - Shareholder dilution

Independent Director recently sold €14m worth of stock

Shockwave Medical, Inc. Provides Earnings Guidance for 2024

Full year 2023 earnings released: EPS: US$4.01 (vs US$6.02 in FY 2022)

Shockwave Medical, Inc. Appoints Renee Gaeta as Chief Financial Officer, Effective February 5, 2024

Shockwave Medical, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 27%

Shockwave Medical, Inc. Announces New Data Demonstrating One-Year Outcomes with Coronary Lithotripsy

Shockwave Medical, Inc. Provides Revenue Guidance for the Full Year 2023

Now 22% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: US$0.95 (vs US$0.97 in 3Q 2022)

Shockwave Medical, Inc. Introduces Enhanced Coronary IVL Catheter in the United States

Shockwave Medical, Inc. Announces New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies

Shockwave Medical, Inc. Appoints Nick West as Associate Chief Medical Officer

Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer

New minor risk - Shareholder dilution

Shockwave Medical, Inc. Revises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.79 (vs US$0.71 in 2Q 2022)

Shockwave Medical, Inc.(NasdaqGS:SWAV) dropped from Russell 2000 Dynamic Index

Shockwave Medical, Inc. Appoints Kevin Ballinger to Board of Directors and Will Serve on Shockwave’s Nominating and ESG Committee and the Compensation Committee of the Board

Key Executive recently sold €548k worth of stock

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

First quarter 2023 earnings released: EPS: US$1.07 (vs US$0.41 in 1Q 2022)

Shockwave Medical, Inc. Revises Revenue Guidance for the Year 2023

Investor sentiment improves as stock rises 15%

Independent Director recently sold €132k worth of stock

Shockwave Medical, Inc. Provides Earnings Guidance for the Full Year 2023

Full year 2022 earnings released: EPS: US$6.02 (vs US$0.26 loss in FY 2021)

ShockWave Medical, Inc. (NasdaqGS:SWAV) entered into a definitive agreement to acquire Neovasc Inc. (TSX:NVCN) from Strul Medical Group LLC and others for $75.04 million.

ShockWave Medical, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2022 and Fiscal Year 2023

ShockWave Medical, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Now 23% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: US$0.97 (vs US$0.055 in 3Q 2021)

ShockWave Medical, Inc. Revises Revenue Guidance for the Year 2022

ShockWave Medical, Inc. Confirms Consistent Outcomes for IVL in the larger Prospective “Real World” Study of Patients with Heavily Calcified Peripheral Arterial Disease

Independent Director recently sold €192k worth of stock

Chief Accounting Officer recently sold €1.1m worth of stock

ShockWave Medical, Inc. Revises Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released: EPS: US$0.71 (vs US$0.012 loss in 2Q 2021)

Shockwave Medical, Inc. and Genesis MedTech Group Successfully Obtains Approval from China’S National Medical Products Administration to Market and Sell the Shockwave IVL System with the Shockwave C2 Coronary IVL Catheters and the Shockwave M5 and S4 Peripheral IVL Catheters in China

Shockwave Ivl Maintains Superiority to Angioplasty in Calcified Peripheral Disease At Two Years

First quarter 2022 earnings released: EPS: US$0.41 (vs US$0.68 loss in 1Q 2021)

ShockWave Medical, Inc. Revised Earnings Guidance for the Full Year 2022

ShockWave Medical, Inc., Annual General Meeting, Jun 23, 2022

Independent Director recently sold €357k worth of stock

Shockwave Medical, Inc. Announces the Global Commercial Availability of the Shockwave M5+ Peripheral IVL Catheter After Receiving Both CE Mark and U.S. Food and Drug Administration Clearance

Shockwave Medical Announces Japanese Regulatory Approval of Coronary IVL

Key Executive recently sold €760k worth of stock

ShockWave Medical, Inc. Announces Executive Changes

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato